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Matrix Metalloproteinases Instrumental in
Wound Healing
Wound healing, the complex process of regenerating der-
mal and epidermal tissue after skin injury, involves inflam-
matory, proliferative, and remodeling phases. Members of
theMMP gene family are essential to the tissue degradation
involved in wound healing; however, the specific function of
individual matrix metalloproteinases (MMPs) in wounded
tissues requires further study. Using mice deficient in
MMP-9, MMP-13, or both, Hattori et al (Am J Pathol 2009,
175:533–546) noted a significant delay in wound closure
and histological re-epithelialization compared with wild-type
mice. Both MMP-13 and MMP-9 played key roles in kera-
tinocyte migration, and MMP-13 contributed to angiogene-
sis and contraction in wound healing as well. Topical wound
treatment with MMP-9, MMP-13, or basic fibroblast growth
factor, which stimulates MMP production, increased the
rate of re-epithelialization in these mice, providing a possi-
ble therapeutic strategy for treating delayed wound healing.
Endothelial-Mesenchymal Transition in Liver
Idiopathic portal hypertension is a form of high blood pres-
sure in the liver that often results from fibrotic blockage of
the peripheral portal veins. Vascular endothelial cells
that undergo endothelial-mesenchymal transition to
acquire matrix-producing myofibroblastic features may
contribute to the fibrosis that causes this blockage.
Kitao et al (Am J Pathol 2009, 175:616–626) demon-
strate that the cytokine transforming growth factor
(TGF)-1 can induce conversion of human dermal mi-
crovascular endothelial cells to collagen-producing
cells and that bone morphogenic protein-7, a member
of the TGF- superfamily, can preserve the endothelial
phenotype. The serum of patients with idiopathic portal
hypertension have elevated levels of TGF-1, but no
difference in levels of bone morphogenic protein-7, as
compared with healthy controls. TGF-1 and bone
morphogenic protein-7 may therefore provide a poten-
tial target and agent, respectively, for treating idiopathic
portal hypertension.
FUT-175 Complements Experimental
Autoimmune Encephalomyelitis
Multiple sclerosis is caused in part by autoreactive T
cells that attack the myelin sheaths of nerves in the
central nervous system. Complement produced during
early antigen-presenting cell/T-cell interactions may
enhance effector T cell responses. Li et al (Am J Pathol
2009, 175:661–667) therefore examined the effects of
FUT-175, a clinical pharmaceutical that prevents com-
plement C3/C5 activation, on the development of ex-
perimental autoimmune encephalomyelitis, a mouse
model of multiple sclerosis. They found that FUT-175
prevented production of C3a/C5a (activation products)
by antigen-presenting cell/T-cell complexes and inhib-
ited specific T cell responses with little nonspecific
cytotoxicity. FUT-175 treatment delayed experimental
autoimmune encephalomyelitis disease onset, lowered
clinical scores, decreased central nervous system in-
flammation, and reduced demyelination by affecting
specific cellular responses rather than autoantibodies.
Thus, FUT-175 may be a novel candidate to treat T-
cell-mediated diseases such as multiple sclerosis.
Omega-3 Fatty Acids Slow Retinal Degeneration
Age-related macular degeneration (AMD), a leading
cause of blindness among the elderly, involves the de-
struction and deterioration of photoreceptors and the
retinal pigment epithelium. Omega-3 polyunsaturated
fatty acids have preventative functions in a number of
diseases and have been suggested as a risk manage-
ment option for AMD. Tuo et al (Am J Pathol 2009, 175:
799–807) examined the role of omega-3 fatty acids in a
mouse model of AMD. A diet high in omega-3 fatty acids
slowed the progression of retinal lesions and decreased
production of pro-inflammatory derivatives in these mice.
Omega-3 fatty acids may therefore provide a viable risk
reduction strategy for AMD.
Phox2B Neural Progenitors Drive
Neuroblastoma Initiation and Progression
Approximately 22% of neuroblastomas, which com-
monly contain undifferentiated or poorly differentiated
neuroblasts, express amplified levels of the oncogene
MYCN. To identify the cell types that drive neuroblastoma
development and clarify the cellular functions and targets
of MYCN in this process, Alam et al (Am J Pathol 2009,
175:856–866) examined TH-MYCN transgenic mice, an
animal model of human neuroblastoma. MYCN enhanced
proliferation and arrested differentiation of Phox2B neu-
ronal progenitors, and both hyperplastic lesions and pri-
mary tumors were composed predominantly of these
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cells. Nestin cells, which may serve as precursors of
Phox2B neuronal progenitors, were also increased in
both hyperplastic lesions and primary neuroblastomas.
These data indicate that the expansion of Phox2B neu-
ronal progenitors may be pathogenic in the development
of neuroblastoma and that MYCN may contribute to this
process by driving the proliferation of the Phox2B neu-
ronal progenitor cell population.
Platelet Endothelial Cell Adhesion Molecule-1 in
Angiogenesis
Platelet endothelial cell adhesion molecule-1 (PECAM-1),
an adhesion molecule expressed on endothelial cells,
leukocytes, and platelets, promotes endothelial cell mo-
tility, and anti-PECAM-1 antibodies impair blood vessel
formation. Cao et al (Am J Pathol 2009, 175:903–915)
further examined the role of PECAM-1 in blood vessel
formation in PECAM-1-deficient mice. Vascularization of
Matrigel implants and tumor angiogenesis were both
inhibited due to loss of endothelial, but not leukocyte,
PECAM-1 expression. Filopodia formation was also in-
hibited in PECAM-1-deficient endothelial cells, which
suggests that PECAM-1 may stimulate filopodia forma-
tion resulting in endothelial cell motility. As PECAM-1
is not required for embryonic vascular development,
PECAM-1 may therefore provide a tumor-specific, low-
toxicity target to inhibit angiogenesis in cancer
patients.
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